Institut National de la Santé et de la Recherche Médicale, ERI-20, EA4045 Paris-Sud Université, and Institut Gustave Roussy, Villejuif, France.
Eur J Cancer Prev. 2010 Mar;19(2):120-5. doi: 10.1097/CEJ.0b013e3283354918.
Metabolic syndrome, including low HDL cholesterol, has been associated with an increased breast cancer risk, whereas little is known of the relationship with total cholesterol. Cox proportional hazards regression models were performed to evaluate the association between self-reported total serum cholesterol, cholesterol-lowering drugs, and risk of breast cancer in 69 088 women from the French E3N cohort study. A total of 2932 cases of primary invasive breast cancer were reported during 12 years of follow-up. Compared with women with low/normal serum cholesterol (<6.6 mol/l), users of cholesterol-lowering drugs had a significantly decreased breast cancer risk [hazard ratio (HR): 0.79, 95% confidence interval (CI): 0.68, 0.93]. There was no variation in HRs according to the menopausal status. In strata defined by the hormone receptor status of the tumor, the risk reached statistical significance only for the estrogen-positive and progesterone-positive receptor subtype (HR: 0.64, 95% CI: 0.50, 0.82). A high cholesterol without cholesterol-lowering drug use was not associated with breast cancer risk (HR: 0.99, 95% CI: 0.85, 1.15) in the entire population. Our result concerning cholesterol-lowering drugs is consistent with studies showing that hypolipidemic molecules are effective in inhibiting cancer cell growth proliferation. Further studies should investigate whether these findings apply to all classes of cholesterol-lowering drugs.
代谢综合征，包括低 HDL 胆固醇，与乳腺癌风险增加有关，而总胆固醇与之相关的关系知之甚少。采用 Cox 比例风险回归模型评估了法国 E3N 队列研究中 69088 名女性自我报告的总血清胆固醇、降胆固醇药物与乳腺癌风险之间的关系。在 12 年的随访中，共报告了 2932 例原发性浸润性乳腺癌病例。与低/正常血清胆固醇(<6.6mol/l)的女性相比，使用降胆固醇药物的女性乳腺癌风险显著降低[风险比 (HR):0.79，95%置信区间 (CI):0.68,0.93]。HR 无随绝经状态变化的差异。在根据肿瘤激素受体状态定义的分层中，仅雌激素阳性和孕激素阳性受体亚型的风险达到统计学意义(HR:0.64,95%CI:0.50,0.82)。在整个人群中，未使用降胆固醇药物的高胆固醇与乳腺癌风险无关(HR:0.99,95%CI:0.85,1.15)。我们关于降胆固醇药物的结果与表明降脂分子可有效抑制癌细胞生长增殖的研究结果一致。进一步的研究应调查这些发现是否适用于所有类别的降胆固醇药物。
